Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16002983 | 0.89 | SYK (0.51) | SYKCHRM1KDM4EAPOBEC3AAPOBEC3G | |
| SCHEMBL16000474 | 0.82 | CHRM2 (0.55) | SYKALDH1A1 | |
| SCHEMBL13826420 | 0.78 | EPHX2 (0.54) | SYKKDM4EALDH1A1 | |
| SCHEMBL16000488 | 0.77 | SYK (0.49) | SYK | |
| SCHEMBL13826657 | 0.76 | MAPK1 (0.56) | KDM4EMEN1KMT2AC3AR1ALDH1A1 | |
| SCHEMBL13826433 | 0.76 | CHRM2 (0.57) | SYK | |
| SCHEMBL13826436 | 0.75 | C3AR1 (0.56) | KDM4EC3AR1ALDH1A1 | |
| SCHEMBL13825990 | 0.74 | KDM4E (0.60) | SYKKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL13826421 | 0.74 | RBP4 (0.53) | SYKKDM4EC3AR1ALDH1A1 | |
| SCHEMBL13826434 | 0.74 | SYK (0.46) | SYKKDM4EAPOBEC3AAPOBEC3GMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145391-B2 | Bipyridylaminopyridines as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249130-A1 | BIPYRIDYLAMINOPYRIDINES AS SYK INHIBITORS | SYK, BTK, LCK | SYK 1/4885CHRM1 567/4885KDM4E 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.